$HBIO
HARVARD BIOSCIENCE INC Stock $hbio

$hbio Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-Q Financial Statement

#000117184315006060 Filed on November 05, 2015

Income Statement

Concept	2015 Q4	2015 Q3	2014 Q3
Revenue	$28.37M	$25.73M	$25.45M
YoY Change	-6.57%	1.11%	1.24%
Cost Of Revenue	$15.45M	$14.01M	$14.01M
YoY Change	-6.39%	-0.01%	1.21%
Gross Profit	$12.92M	$11.73M	$11.44M
YoY Change	-6.77%	2.48%	1.27%
Gross Profit Margin	45.56%	45.57%	44.96%
Selling, General & Admin	$10.30M	$10.03M	$8.243M
YoY Change	7.63%	21.72%	-6.54%
% of Gross Profit	79.7%	85.56%	72.04%
Research & Development	$1.530M	$1.426M	$1.059M
YoY Change	-1.92%	34.66%	-45.24%
% of Gross Profit	11.84%	12.16%	9.26%
Depreciation & Amortization	$1.270M	$1.060M	$930.0K
YoY Change	16.51%	13.98%	-3.13%
% of Gross Profit	9.83%	9.04%	8.13%
Operating Expenses	$12.81M	$12.50M	$10.02M
YoY Change	9.1%	24.8%	-7.97%
Operating Profit	$113.0K	-$775.0K	$1.425M
YoY Change	-94.67%	-154.39%	244.2%
Interest Expense	-$160.0K	$204.0K	$239.0K
YoY Change	-23.81%	-14.64%	-13.41%
% of Operating Profit	-141.59%		16.77%
Other Income/Expense, Net	-$434.0K	-$321.0K	-$469.0K
YoY Change	-54.27%	-31.56%	31.01%
Pretax Income	-$321.0K	-$1.096M	$956.0K
YoY Change	-127.39%	-214.64%	1607.14%
Income Tax	$16.82M	-$249.0K	$323.0K
% Of Pretax Income			33.79%
Net Earnings	-$17.14M	-$847.0K	$633.0K
YoY Change	90110.53%	-233.81%	-164.33%
Net Earnings / Revenue	-60.42%	-3.29%	2.49%
Basic Earnings Per Share	-$0.51	-$0.02	$0.02
Diluted Earnings Per Share	-$0.51	-$0.02	$0.02
COMMON SHARES
Basic Shares Outstanding	33.94M shares	33.93M shares	32.34M shares
Diluted Shares Outstanding		33.93M shares	33.41M shares

Balance Sheet

Concept	2015 Q4	2015 Q3	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.700M	$6.100M	$26.70M
YoY Change	-52.48%	-77.15%	-27.64%
Cash & Equivalents	$6.744M	$6.090M	$26.73M
Short-Term Investments
Other Short-Term Assets	$3.873M	$5.070M	$4.062M
YoY Change	-18.33%	24.82%	153.88%
Inventory	$22.34M	$23.01M	$18.06M
Prepaid Expenses
Receivables	$17.55M	$15.59M	$14.28M
Other Receivables	$3.900M	$5.100M	$4.000M
Total Short-Term Assets	$50.55M	$52.32M	$65.00M
YoY Change	-11.42%	-19.5%	-12.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.902M	$5.934M	$4.109M
YoY Change	13.72%	44.41%	-10.67%
Goodwill	$40.36M	$40.86M	$35.94M
YoY Change	1.34%	13.69%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$152.0K	$349.0K	$359.0K
YoY Change	-60.0%	-2.79%	-97.2%
Total Long-Term Assets	$69.50M	$81.23M	$71.13M
YoY Change	-11.86%	14.21%	-4.4%
TOTAL ASSETS
Total Short-Term Assets	$50.55M	$52.32M	$65.00M
Total Long-Term Assets	$69.50M	$81.23M	$71.13M
Total Assets	$120.1M	$133.6M	$136.1M
YoY Change	-11.67%	-1.89%	-8.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.782M	$6.322M	$5.100M
YoY Change	39.53%	23.96%	8.51%
Accrued Expenses	$4.021M	$3.840M	$4.132M
YoY Change	-9.68%	-7.07%	-6.09%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.400M	$5.000M	$5.000M
YoY Change	-52.0%	0.0%	66.67%
Total Short-Term Liabilities	$19.32M	$17.27M	$15.63M
YoY Change	6.76%	10.51%	15.76%
LONG-TERM LIABILITIES
Long-Term Debt	$16.37M	$15.15M	$18.20M
YoY Change	-0.49%	-16.76%	-11.22%
Other Long-Term Liabilities	$3.000M	$4.600M	$5.400M
YoY Change	-34.78%	-14.81%	-12.9%
Total Long-Term Liabilities	$16.37M	$15.15M	$18.20M
YoY Change	-0.49%	-16.76%	-31.84%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.32M	$17.27M	$15.63M
Total Long-Term Liabilities	$16.37M	$15.15M	$18.20M
Total Liabilities	$42.45M	$39.27M	$39.35M
YoY Change	4.95%	-0.21%	-2.83%
SHAREHOLDERS EQUITY
Retained Earnings	-$111.7M	-$94.58M	-$92.67M
YoY Change	20.54%	2.06%
Common Stock	$211.9M	$211.1M	$205.8M
YoY Change	2.33%	2.57%	53769.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares	7.746M shares	7.746M shares
Shareholders Equity	$77.60M	$94.29M	$96.78M
YoY Change
Total Liabilities & Shareholders Equity	$120.1M	$133.6M	$136.1M
YoY Change	-11.67%	-1.89%	-8.21%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2014 Q3
OPERATING ACTIVITIES
Net Income	-$17.14M	-$847.0K	$633.0K
YoY Change	90110.53%	-233.81%	-164.33%
Depreciation, Depletion And Amortization	$1.270M	$1.060M	$930.0K
YoY Change	16.51%	13.98%	-3.13%
Cash From Operating Activities	$1.770M	-$80.00K	$600.0K
YoY Change	40.48%	-113.33%	-58.04%
INVESTING ACTIVITIES
Capital Expenditures	-$680.0K	-$660.0K	-$480.0K
YoY Change	-13.92%	37.5%	-5.88%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$10.00K	$0.00
YoY Change	-100.0%		-100.0%
Cash From Investing Activities	-$680.0K	-$670.0K	-$480.0K
YoY Change	-94.5%	39.58%	-137.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.160M	-410.0K	1.360M
YoY Change	6.42%	-130.15%	-281.33%
NET CHANGE
Cash From Operating Activities	1.770M	-80.00K	600.0K
Cash From Investing Activities	-680.0K	-670.0K	-480.0K
Cash From Financing Activities	-1.160M	-410.0K	1.360M
Net Change In Cash	-70.00K	-1.160M	1.480M
YoY Change	-99.43%	-178.38%	-24.1%
FREE CASH FLOW
Cash From Operating Activities	$1.770M	-$80.00K	$600.0K
Capital Expenditures	-$680.0K	-$660.0K	-$480.0K
Free Cash Flow	$2.450M	$580.0K	$1.080M
YoY Change	19.51%	-46.3%	-44.33%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	868000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.51
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	-272121	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	3.98
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6263112	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5119857	shares
CY2014Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	3.42
CY2015Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	3.87
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	323894	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.04
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	-237188	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	4.3
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	5.3
	hbio	Stock Issued During Period Gross Stock Options Exercised StockIssuedDuringPeriodGrossStockOptionsExercised	1739134	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33097012	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.56
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4107	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0172	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M7D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.5683	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0179	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M0D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation ShareBasedCompensation	1534000	USD
CY2015Q3	hbio	Percentage Of Outstanding Common Stock PercentageOfOutstandingCommonStock	0.2	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate	0.85	pure
CY2015Q3	hbio	Employee Stock Purchase Plan Shares Authorized EmployeeStockPurchasePlanSharesAuthorized	750000	shares
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	611369	shares
CY2015Q3	hbio	Lender Approval To Fund Acquisition With Cash Promissory Note In Excess Of Threshold LenderApprovalToFundAcquisitionWithCashPromissoryNoteInExcessOfThreshold	6000000	USD
CY2015Q3	hbio	Lender Approval To Fund Acquisition With Equity In Excess Of Threshold LenderApprovalToFundAcquisitionWithEquityInExcessOfThreshold	10000000	USD
CY2009Q3	hbio	Previous Approved Credit Facility PreviousApprovedCreditFacility	20000000	USD
CY2013Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	50000000	USD
CY2013Q1	hbio	Ddtl Threshold For Dollar For Dollar Reduction In Revolving Line DdtlThresholdForDollarForDollarReductionInRevolvingLine	10000000	USD
CY2009Q3	hbio	Interest Rate In Excess Of Libor On Credit Facility InterestRateInExcessOfLiborOnCreditFacility	0.03	pure
CY2015Q3	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	5600000	USD
CY2013Q4	hbio	Transferof Delayed Draw Down Term Loan Capacity To Revolver Capacity TransferofDelayedDrawDownTermLoanCapacityToRevolverCapacity	5000000	USD
	us-gaap	Derivative Instruments Gain Loss Reclassification From Accumulated Oci To Income Estimated Net Amount To Be Transferred DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred	100000	USD
	hbio	Derivative Interest Rate Swap Effective Percentage DerivativeInterestRateSwapEffectivePercentage	1	pure
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16141000	USD
CY2014Q4	us-gaap	Assets Assets	135916000	USD
CY2014Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1252000	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4742000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	20531000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	11056000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	21153000	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	328000	USD
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40308763	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32563256	shares
CY2014Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	7745507	shares
CY2014Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	1515000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	57063000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	380000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6294000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	655000	USD
CY2014Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	554000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4452000	USD
CY2014Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1023000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18099000	USD
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	16450000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	1325000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	4574000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	40448000	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	397000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	206656000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-92684000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8233000	USD
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Operating Expenses OperatingExpenses	30984000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	4497000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1252000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	3245000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	871000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2014Q4	us-gaap	Treasury Stock Carrying Basis TreasuryStockCarryingBasis	10668000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	135916000	USD
CY2015Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15590000	USD
CY2015Q3	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	2563000	USD
CY2015Q3	us-gaap	Other Assets Current OtherAssetsCurrent	5070000	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	52324000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5934000	USD
CY2015Q3	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	11046000	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	21813000	USD
CY2015Q3	us-gaap	Goodwill Goodwill	40858000	USD
CY2015Q3	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1231000	USD
CY2015Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	349000	USD
CY2015Q3	us-gaap	Assets Assets	133555000	USD
CY2015Q3	us-gaap	Inventory Net InventoryNet	23011000	USD
CY2015Q3	us-gaap	Secured Debt Current SecuredDebtCurrent	5000000	USD
CY2015Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	6322000	USD
CY2015Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	795000	USD
CY2015Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	214000	USD
CY2015Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3840000	USD
CY2015Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	855000	USD
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	17270000	USD
CY2015Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	15150000	USD
CY2015Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	2256000	USD
CY2015Q3	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	4593000	USD
CY2015Q3	us-gaap	Liabilities Liabilities	39269000	USD
CY2015Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	416000	USD
CY2015Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	210655000	USD
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-94583000	USD
CY2015Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-11534000	USD
CY2015Q3	us-gaap	Treasury Stock Carrying Basis TreasuryStockCarryingBasis	10668000	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	133555000	USD
CY2015Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	330000	USD
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41689714	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33944207	shares
CY2014Q4	us-gaap	Goodwill Goodwill	39822000	USD
CY2014Q4	us-gaap	Secured Debt SecuredDebt	21450000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14134000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6090000	USD
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	94286000	USD
CY2015Q3	us-gaap	Revenues Revenues	25731000	USD
CY2015Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14005000	USD
CY2015Q3	us-gaap	Gross Profit GrossProfit	11726000	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	12501000	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-321000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1024000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-769000	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1096000	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-249000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-847000	USD
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
	us-gaap	Net Income Loss NetIncomeLoss	2374000	USD
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
CY2015Q3	us-gaap	Deferred Tax Liabilities Current DeferredTaxLiabilitiesCurrent	244000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Current DeferredTaxLiabilitiesCurrent	121000	USD
CY2014	hbio	Minimun Percentage Of Term Loan And Delayed Draw Term Loan On Which Interest Rate Required To Be Fixed MinimunPercentageOfTermLoanAndDelayedDrawTermLoanOnWhichInterestRateRequiredToBeFixed	0.5	pure
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33473958	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32079744	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1017268	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33473958	shares
	dei	Trading Symbol TradingSymbol	HBIO
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5190000	USD
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2015Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	7745507	shares
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	33944207	shares
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	HARVARD BIOSCIENCE INC
	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
CY2015Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5028000	USD
CY2014Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4113000	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5005000	USD
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4130000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1426000	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1059000	USD
CY2015Q3	us-gaap	Restructuring Charges RestructuringCharges	376000	USD
CY2014Q3	us-gaap	Restructuring Charges RestructuringCharges	97000	USD
CY2015Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	666000	USD
CY2014Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	618000	USD
CY2015Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	70000	USD
CY2014Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	204000	USD
CY2014Q3	us-gaap	Interest Expense InterestExpense	239000	USD
CY2015Q3	us-gaap	Other Interest And Dividend Income OtherInterestAndDividendIncome	1000	USD
CY2014Q3	us-gaap	Other Interest And Dividend Income OtherInterestAndDividendIncome	19000	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-188000	USD
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-249000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	2049000	USD
	us-gaap	Depreciation Depreciation	1157000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-25000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-8000	USD
	hbio	Non Cash Restructuring Charge NonCashRestructuringCharge	-79000	USD
	hbio	Non Cash Restructuring Charge NonCashRestructuringCharge	-120000	USD
	hbio	Amortization Of Catalog Costs AmortizationOfCatalogCosts	8000	USD
	hbio	Amortization Of Catalog Costs AmortizationOfCatalogCosts	37000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-34000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	58000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	46000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	259000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-754000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	557000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1310000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2649000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	407000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	466000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	35000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	446000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-362000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-107000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2046000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-486000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	158000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-38000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-316000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	89000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1059000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3088000	USD
	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	-2298000	USD
	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	-1224000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	6000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	76000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	4545000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6837000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1148000	USD
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	4800000	USD
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	2200000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	6100000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	3750000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1953000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1415000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	621000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-135000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-842000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-8044000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	963000	USD
	us-gaap	Interest Paid InterestPaid	625000	USD
	us-gaap	Interest Paid InterestPaid	757000	USD
CY2014	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	49000	USD
CY2015Q3	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	146000	USD
CY2014Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	252000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	625000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	451000	USD
CY2015Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	10169000	USD
CY2015Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	949000	USD
CY2015Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	11893000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	21579000	USD
CY2015Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15645000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1803000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1705000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1688000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1490000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1490000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	4508000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	12684000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1839000	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2800000	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2800000	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2500000	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2300000	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2200000	USD
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-526000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-3168000	USD
CY2015Q3	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-39000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	23000	USD
CY2015Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-22000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-31000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1390000	USD
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2481000	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	48040000	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-26227000	USD
CY2015Q3	hbio	Total Indefinite Lived Intangible Assets Including Goodwill TotalIndefiniteLivedIntangibleAssetsIncludingGoodwill	42089000	USD
CY2015Q3	hbio	Total Intangible Assets TotalIntangibleAssets	90129000	USD
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	2061000	USD
	us-gaap	Goodwill Translation Adjustments GoodwillTranslationAdjustments	-1025000	USD
CY2015Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	600000	USD
	us-gaap	Defined Benefit Plans Estimated Future Employer Contributions In Current Fiscal Year DefinedBenefitPlansEstimatedFutureEmployerContributionsInCurrentFiscalYear	200000	USD
CY2015Q3	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	4500000	USD
CY2015Q3	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	200000	USD
CY2014Q3	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	200000	USD
CY2014Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	4400000	USD
CY2015Q3	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	175000	USD
CY2015Q3	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	165000	USD
CY2014Q3	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	147000	USD
CY2015Q3	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-75000	USD
CY2014Q3	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-40000	USD
CY2015Q3	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	85000	USD
CY2014Q3	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	93000	USD
CY2014	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	-102000	USD
	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	-73000	USD
	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	-33000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25771000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26734000	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0001123494
	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-3373000	USD
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-72000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3301000	USD
CY2015Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5640536	shares
CY2014Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2449873	shares
CY2015Q3	us-gaap	Secured Debt SecuredDebt	20150000	USD
	hbio	Minimun Percentage Of Term Loan And Delayed Draw Term Loan On Which Interest Rate Required To Be Fixed MinimunPercentageOfTermLoanAndDelayedDrawTermLoanOnWhichInterestRateRequiredToBeFixed	0.5	pure
CY2014Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.338	pure
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	20200000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15010000	USD
CY2014Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	10138000	USD
CY2014Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	946000	USD
CY2014Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	9447000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	15355000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	13102000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14758000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12378000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4888000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3316000	USD
	us-gaap	Restructuring Charges RestructuringCharges	487000	USD
	us-gaap	Restructuring Charges RestructuringCharges	349000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2137000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	159000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-148000	USD
	us-gaap	Interest Expense InterestExpense	641000	USD
	us-gaap	Interest Expense InterestExpense	752000	USD
	us-gaap	Other Interest And Dividend Income OtherInterestAndDividendIncome	5000	USD
	us-gaap	Other Interest And Dividend Income OtherInterestAndDividendIncome	45000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-984000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-397000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-3263000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-2584000	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-110000	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-57000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-72000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-100000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5200000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-651000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2015Q3	hbio	Business Acquisition Direct Acquisition Costs In Income Statement BusinessAcquisitionDirectAcquisitionCostsInIncomeStatement	200000	USD
CY2014Q3	hbio	Business Acquisition Direct Acquisition Costs In Income Statement BusinessAcquisitionDirectAcquisitionCostsInIncomeStatement	300000	USD
	hbio	Business Acquisition Direct Acquisition Costs In Income Statement BusinessAcquisitionDirectAcquisitionCostsInIncomeStatement	900000	USD
	hbio	Business Acquisition Direct Acquisition Costs In Income Statement BusinessAcquisitionDirectAcquisitionCostsInIncomeStatement	400000	USD
CY2014Q4	hbio	Total Indefinite Lived Intangible Assets Including Goodwill TotalIndefiniteLivedIntangibleAssetsIncludingGoodwill	41074000	USD
CY2014Q4	hbio	Total Intangible Assets TotalIntangibleAssets	86712000	USD
CY2013Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	305000	USD
	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	542000	USD
	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	649000	USD
	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	510000	USD
	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	478000	USD
	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-231000	USD
	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-131000	USD
	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	263000	USD
	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	302000	USD
	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	600000	USD
CY2014Q3	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	200000	USD
	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	600000	USD
CY2014Q3	hbio	Fair Value Impairment Of Pension Assets FairValueImpairmentOfPensionAssets	600000	USD
CY2014Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	300000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1100000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1800000	USD
	hbio	Estimated Rental Expenses Current Year EstimatedRentalExpensesCurrentYear	2200000	USD
CY2015Q3	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	0	USD
CY2014Q3	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	484000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	254685	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.3947	pure
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.5696	pure
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0176	pure
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.019	pure
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y3M0D
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M4D
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2015Q3	us-gaap	Share Based Compensation ShareBasedCompensation	777000	USD
CY2014Q3	us-gaap	Share Based Compensation ShareBasedCompensation	615000	USD
CY2015Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	80000	USD
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33933327	shares
CY2014Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32341586	shares
CY2015Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2014Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1073271	shares
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33933327	shares
CY2014Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33414857	shares
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.423	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.268	pure
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	26181	shares
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	31116	shares
CY2015Q3	hbio	Weighted Average Estimated Black Scholes Value Of Option Grants WeightedAverageEstimatedBlackScholesValueOfOptionGrants	2.14
CY2014Q3	hbio	Weighted Average Estimated Black Scholes Value Of Option Grants WeightedAverageEstimatedBlackScholesValueOfOptionGrants	2.64
	hbio	Weighted Average Estimated Black Scholes Value Of Option Grants WeightedAverageEstimatedBlackScholesValueOfOptionGrants	2.21
	hbio	Weighted Average Estimated Black Scholes Value Of Option Grants WeightedAverageEstimatedBlackScholesValueOfOptionGrants	2.2
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5640536	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2535314	shares
CY2015Q2	hbio	Increase In Number Of Shares Authorized For Issuance Under Stock Option And Incentive Plan IncreaseInNumberOfSharesAuthorizedForIssuanceUnderStockOptionAndIncentivePlan	2500000	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	17508929	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	100000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	32000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div><p style='text-align:left;margin-top:9pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0pt;' >2</font><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;' >.</font><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;' > Recently Issued Accounting Pronouncements</font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Calibri;font-size:11pt;font-weight:bold;margin-left:0pt;' > </font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' >In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >“Revenue from Contracts with Customers,”</font><font style='font-family:Times New Roman;font-size:10pt;' > a new accounting standard that provides for a comprehensive model to use in the accounting for revenue arising from contracts with customers that will replace most existing revenue recognition guidance in U.S. GAAP. Under this standard, revenue will be re</font><font style='font-family:Times New Roman;font-size:10pt;' >cognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. At its July 2015 meeting, the FASB agreed to defer </font><font style='font-family:Times New Roman;font-size:10pt;' >the mandatory effective date of ASU 2014-09 one year. Under the one year deferral, the standard will take effect in 2018 for calendar year-end public entities. The Company is assessing the new standard and has not yet determined the impact to the consolida</font><font style='font-family:Times New Roman;font-size:10pt;' >ted financial statements. </font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' >In April 2015, the FASB issued ASU 2015-03, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</font><font style='font-family:Times New Roman;font-size:10pt;' >. The update requires debt issuance costs related to a recognized debt liabili</font><font style='font-family:Times New Roman;font-size:10pt;' >ty to be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability, instead of being presented as an asset. Debt disclosures will include the face amount of the debt liability and the effective interest rat</font><font style='font-family:Times New Roman;font-size:10pt;' >e. The update requires retrospective application and represents a change in accounting principle. The update is effective for fiscal years beginning after December 15, 2015.  Early adoption is permitted for financial statements that have not been previousl</font><font style='font-family:Times New Roman;font-size:10pt;' >y issued. The Company is evaluating the impact of ASU 2015-03 on its consolidated financial statements and the possibility of early adoption by the Company.</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' >In July 2015, the FASB issued ASU 2015-11, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >Simplifying Measurement of Inventory</font><font style='font-family:Times New Roman;font-size:10pt;' >. The update requir</font><font style='font-family:Times New Roman;font-size:10pt;' >es measurement of most inventory “at the lower of cost and net realizable value”, and applies to all entities that recognize inventory within the scope of ASC 330, except for inventory measured under the last-in, first-out (LIFO) method or the retail inven</font><font style='font-family:Times New Roman;font-size:10pt;' >tory method (RIM). ASU 2015-11 requires prospective application and represents a change in accounting principle. The update is effective for fiscal years beginning after December 15, 2016.  Early adoption is permitted for financial statements that have not</font><font style='font-family:Times New Roman;font-size:10pt;' > been previously issued. The Company is evaluating the impact of ASU 2015-11 on its consolidated financial statements and the possibility of early adoption by the Company.</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' >In September 2015, the FASB issued ASU 2015-16, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >Simplifying the Accounting for Meas</font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >urement-Period Adjustments</font><font style='font-family:Times New Roman;font-size:10pt;' >. The update eliminates the requirement to retrospectively adjust financial statements for measurement-period adjustments that occur in periods after a business combination. Under the update, measurement-period adjustments are to </font><font style='font-family:Times New Roman;font-size:10pt;' >be calculated as if they were known at the acquisition date, but are recognized in the reporting period in which they are determined. Additional disclosures are required about the impact on current-period earnings. ASU 2015-16 requires prospective applicat</font><font style='font-family:Times New Roman;font-size:10pt;' >ion to adjustments of provisional amounts that occur after the effective date. The update is effective for fiscal years beginning after December 15, 2016.  Early adoption is permitted for financial statements that have not been previously issued. The Compa</font><font style='font-family:Times New Roman;font-size:10pt;' >ny is evaluating the impact of ASU 2015-16 on its consolidated financial statements and the possibility of early adoption by the Company.</font></p></div>

Files In Submission

Name	View Source	Status
0001171843-15-006060-index-headers.html	Edgar Link	pending
0001171843-15-006060-index.html	Edgar Link	pending
0001171843-15-006060.txt	Edgar Link	pending
0001171843-15-006060-xbrl.zip	Edgar Link	pending
exh_101.htm	Edgar Link	pending
exh_311.htm	Edgar Link	pending
exh_312.htm	Edgar Link	pending
exh_321.htm	Edgar Link	pending
exh_322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gff10q_110515.htm	Edgar Link	pending
hbio-20150930.xml	Edgar Link	completed
hbio-20150930.xsd	Edgar Link	pending
hbio-20150930_cal.xml	Edgar Link	unprocessable
hbio-20150930_def.xml	Edgar Link	unprocessable
hbio-20150930_lab.xml	Edgar Link	unprocessable
hbio-20150930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HBIO
HARVARD BIOSCIENCE INC Stock $hbio

2015 Q4 Form 10-Q Financial Statement

#000117184315006060 Filed on November 05, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HBIO HARVARD BIOSCIENCE INC Stock $hbio

2015 Q4 Form 10-Q Financial Statement

#000117184315006060 Filed on November 05, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HBIO
HARVARD BIOSCIENCE INC Stock $hbio